EXH.03 / FAQ
questions the record can actually answer
Twelve common review-style questions about AOD-9604, each answered from the published research and regulatory record.
What is AOD-9604, and how does it differ from full human growth hormone?
AOD-9604 is a synthetic 16-amino-acid peptide — a hexadecapeptide — built from the C-terminal lipolytic fragment of human growth hormone (residues 177-191) with an added N-terminal tyrosine, and a disulfide bridge between its two cysteines that mimics the parent hormone's cystine loop [1][20]. The molecule was designed to deliver the fat-mobilising activity of intact hGH without engaging the growth hormone receptor, raising IGF-1, or impairing glucose tolerance — three properties that distinguish it from full hGH and that were the explicit design goals of Prof. Frank Ng's Monash group in the 1990s [3][6][20][21]. The published clinical programme confirmed those separation properties: across roughly 900 subjects in six trials, IGF-1 did not rise clinically meaningfully, glucose tolerance did not shift, and no anti-AOD-9604 antibodies were detected [6][21].
Does AOD-9604 actually work for fat loss? What does the clinical evidence say?
The honest answer from the published record is: a short-term Phase IIa signal did not survive a 24-week Phase IIb pivotal at scale. In the 12-week METAOD005 dose-finding study (n=300, oral 1-30 mg daily), the 1 mg arm lost on average 2.6 kg compared with 0.8 kg for placebo — a statistically significant short-term separation [4]. In the 24-week pivotal METAOD006 (n=502, oral 0.25, 0.5, 1 mg daily), none of the three oral arms separated from placebo by a statistically significant margin on the primary weight-loss endpoint, and Metabolic Pharmaceuticals discontinued the obesity programme in February 2007 [5]. Online claims of dramatic human fat-loss outcomes for AOD-9604 do not have a controlled-trial basis in the published Phase II record; the controlled Phase IIb data point in the opposite direction.
Why did the Phase IIb OPTIONS trial fail?
The Phase IIb pivotal (METAOD006, 24 weeks, n=502, three oral doses 0.25-1 mg daily) did not show statistically significant weight loss versus placebo on its primary endpoint [5]. The most parsimonious read on the result — which is the read the published programme summary effectively endorses — is that the 12-week signal in METAOD005 did not persist at 24 weeks and did not generalise to a larger population at the narrower dose range chosen for the pivotal [5][6]. The published programme summary does not invoke a pharmacokinetic or safety reason for the negative result; the safety pool across all six trials was indistinguishable from placebo [6]. The pivotal closed the obesity development question. No subsequent randomised controlled trial of AOD-9604 for obesity has been registered.
What did the FDA say about AOD-9604 in December 2024?
On December 4, 2024, the FDA Pharmacy Compounding Advisory Committee voted that AOD-9604 — both the free base and acetate forms — should not be added to the Section 503A Bulk Drug Substances List [14]. The cited concerns were limited long-term safety data, peptide-impurity profile, and immunogenicity risk. The practical effect is that 503A pharmacies in the United States can no longer use AOD-9604 as a bulk substance to prepare patient-specific compounded medications. A public-testimony submission urging the opposite conclusion (the 'Saving AOD9604' compounding-pharmacy submission), which leaned on the GRAS nutraceutical pathway and observational clinical use, did not change the committee's outcome [22]. The PCAC briefing dossier also documented zero AOD-9604-attributed adverse-event reports in FAERS through January 2024 and in CAERS from January 2004 through April 2024 — a number that is striking but expected for a compound that has not been an approved drug and has not been legally compoundable through 503A [13].
Is AOD-9604 banned by WADA?
Yes. AOD-9604 falls under Section S2 of the WADA Prohibited List (Peptide Hormones, Growth Factors, Related Substances and Mimetics), which explicitly covers growth hormone and its 'fragments and releasing factors' [16]. As a synthetic fragment derived from hGH residues 177-191, AOD-9604 sits squarely inside that category and is prohibited at all times — both in and out of competition — for athletes subject to the WADA Code [16]. USADA, the IOC, NCAA, and most major sport bodies follow the WADA List. A validated LC-MS/MS detection assay for AOD-9604 in human urine has been published in Drug Testing and Analysis (Cox et al., 2015) [12].
What is AOD-9604's mechanism of action at the adipocyte level?
The published rodent mechanism is reasonably well-characterised downstream and partially characterised upstream. Downstream, AOD-9604 engages the standard adipocyte lipolytic cascade — β3-adrenergic receptor activation → cAMP elevation → protein kinase A → phosphorylation of hormone-sensitive lipase → hydrolysis of intracellular triglyceride into glycerol and free fatty acids [21]. β3-AR mRNA is upregulated in white adipose tissue during chronic treatment in obese mice, restoring suppressed levels back toward lean-control values [3]. Chronic weight loss depends on functional β3-AR signalling; β3-AR knockout mice do not lose weight on chronic AOD-9604, although they retain a residual acute fat-oxidation response — implying at least one β3-AR-independent acute pathway as well [3]. AOD-9604 does not bind the growth hormone receptor [6]. The upstream cell-surface receptor that AOD-9604 itself engages on adipocytes — the binding partner that triggers β3-AR upregulation — has not been definitively identified in published work [21].
What does the research say about AOD-9604 and cartilage repair?
The cartilage-repair claim for AOD-9604 rests primarily on one published in-vivo study: Kwon & Park 2015, a collagenase-induced knee osteoarthritis model in 32 New Zealand white rabbits randomised across four arms (saline, hyaluronic acid alone at 6 mg, AOD-9604 alone at 0.25 mg, and combination AOD-9604 + hyaluronic acid) [9]. Weekly ultrasound-guided intra-articular injection over four to seven weeks. The combination arm shortened the lameness-recovery period to 11 ± 4 days versus 15 ± 3 days for HA alone, 16 ± 2 days for AOD-9604 alone, and 25 ± 2 days for saline (all p<0.05 versus saline), and produced the lowest histopathology score [9]. A 2024 Cartilage review lists AOD-9604 in its peptide table on the basis of this study [10]. No human cartilage trial of AOD-9604 has been registered in ClinicalTrials.gov, EudraCT, or the Australian New Zealand Clinical Trials Registry [10][16]. The cartilage-repair evidence base is preclinical.
Is AOD-9604 safe?
The published safety record is unusual among research peptides for its size and consistency. Across the six Metabolic Pharmaceuticals trials (~900 subjects, IV doses 25-400 μg/kg single and oral doses 0.25-54 mg/day for up to 24 weeks), safety and tolerability were indistinguishable from placebo, IGF-1 did not rise clinically meaningfully, oral glucose tolerance did not shift, no anti-AOD-9604 antibodies were detected, and the higher oral arms (≥54 mg) were associated only with mild gastrointestinal complaints [6][21]. A small number of serious adverse events in long-term arms (skin cancers, lipoma, breast cancer) were judged by investigators to be unrelated to study drug [6]. The chronic toxicology established NOAELs of 100 mg/kg/day in a 6-month rat study and 50 mg/kg/day in a 9-month cynomolgus monkey study, with all genotoxicity panels negative [7]. None of this evidence speaks to long-term safety at injectable or supratherapeutic doses, none of it speaks to the safety of compounded or research-peptide preparations of uncertain purity, and the December 2024 FDA PCAC vote cited limited long-term safety data and peptide-impurity concerns as reasons not to add the compound to the 503A Bulks List [14].
What is AOD-9604's pharmacokinetic profile?
Plasma half-life is short: approximately 3-4 minutes after IV administration in pigs, with the intact molecule undetectable approximately 56 minutes after an IV bolus [8]. The principal metabolic pathway is rapid sequential proteolysis from the N-terminus, generating -1aa, -2aa, and -3aa fragments as the dominant degradation products [8]. Oral bioavailability in rats is approximately 40%, which underpinned the choice of oral capsule format for the human Phase II programme [8]. Tissue distribution studies in rats showed preferential uptake in pancreas, pineal gland, thyroid, liver, and kidney cortex [8]. The intramolecular disulfide bridge contributes to lyophilised stability; plasma stability is short.
Does AOD-9604 raise IGF-1 or affect blood glucose?
Not at the doses studied in the Metabolic Pharmaceuticals Phase I/II programme. Across all six METAOD trials (~900 subjects total, IV doses 25-400 μg/kg single and oral doses 0.25-54 mg/day for up to 24 weeks), no clinically significant IGF-1 elevation was observed and oral glucose tolerance did not shift from baseline [6][21]. AOD-9604 does not bind the growth hormone receptor, which is the mechanistic basis for the IGF-1 separation [6][20]. This is a substantial design success: the molecule preserves the lipolytic activity of hGH's C-terminal fragment while not engaging the GHR-driven growth and metabolic effects that are responsible for IGF-1 elevation and glucose modulation with intact hGH.
What is the difference between GRAS self-affirmation and FDA drug approval?
GRAS (Generally Recognized as Safe) is a U.S. regulatory status for food ingredients that have been determined to be safe at intended use levels, either through scientific consensus or through qualified-expert review. AOD-9604 has a self-affirmed GRAS status for use as a food, beverage, and dietary-supplement ingredient at approximately 1 mg per serving, supported by the rat 6-month and monkey 9-month NOAELs and the human Phase I/II safety pool [7][15]. Two important qualifications: 'self-affirmation' means the conclusion was reached by qualified experts engaged by the sponsor rather than affirmed by FDA itself, and the GRAS scope covers low-mg oral nutraceutical use only. It is not an FDA drug approval; it does not apply to injectable or compounded preparations; and it does not authorise the higher-milligram doses sold by research-peptide vendors or used in wellness-clinic contexts [15].
Who developed AOD-9604, and what is the development history?
AOD-9604 was designed in the 1990s by Prof. Frank Ng's group at Monash University in Melbourne as a synthetic mimetic of the lipolytic C-terminal domain of human growth hormone [20]. Clinical development was undertaken by Metabolic Pharmaceuticals Ltd. (Australia), which ran the six METAOD trials between 2001 and 2007 [4][5][6]. After the Phase IIb pivotal failed and the obesity programme was discontinued in February 2007, the corporate successor Calzada Ltd. repositioned the molecule toward an intra-articular osteoarthritis / cartilage-repair indication and generated the preclinical chondrocyte and rabbit-knee evidence (Kwon & Park 2015) that the 2024 Cartilage review now cites [9][10][17]. The 2024 FDA PCAC decision and the WADA Section S2 prohibition are the most recent regulatory entries on the compound's record [14][16].